Bicocca Open Archive

Logo unimib boa
CORTESI, PAOLO ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.705
AS - Asia 9.531
EU - Europa 7.800
SA - Sud America 1.416
AF - Africa 198
OC - Oceania 44
Continente sconosciuto - Info sul continente non disponibili 13
Totale 32.707
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.326
SG - Singapore 3.795
CN - Cina 2.023
IT - Italia 1.967
HK - Hong Kong 1.544
RU - Federazione Russa 1.285
BR - Brasile 1.154
DE - Germania 1.093
VN - Vietnam 1.033
SE - Svezia 707
IE - Irlanda 671
GB - Regno Unito 412
UA - Ucraina 385
FR - Francia 339
CA - Canada 246
IN - India 216
FI - Finlandia 194
ID - Indonesia 192
DK - Danimarca 148
AT - Austria 141
NL - Olanda 123
TR - Turchia 122
KR - Corea 116
AR - Argentina 112
MX - Messico 95
BD - Bangladesh 86
ZA - Sudafrica 83
ES - Italia 60
PL - Polonia 55
IQ - Iraq 52
JP - Giappone 49
BE - Belgio 47
IR - Iran 46
EC - Ecuador 41
PK - Pakistan 38
CH - Svizzera 37
AU - Australia 36
VE - Venezuela 27
PH - Filippine 25
UZ - Uzbekistan 25
CL - Cile 22
MA - Marocco 22
AE - Emirati Arabi Uniti 21
CZ - Repubblica Ceca 21
KE - Kenya 21
CO - Colombia 20
RO - Romania 20
SA - Arabia Saudita 20
EG - Egitto 17
BG - Bulgaria 16
TH - Thailandia 15
PY - Paraguay 14
ET - Etiopia 13
LT - Lituania 13
MY - Malesia 13
JO - Giordania 12
TW - Taiwan 12
AL - Albania 11
BO - Bolivia 11
EU - Europa 11
PT - Portogallo 11
DZ - Algeria 10
IL - Israele 10
NO - Norvegia 10
PE - Perù 10
TN - Tunisia 9
LB - Libano 8
NP - Nepal 8
CR - Costa Rica 7
DO - Repubblica Dominicana 7
GR - Grecia 7
JM - Giamaica 7
LK - Sri Lanka 7
NZ - Nuova Zelanda 7
KZ - Kazakistan 6
NG - Nigeria 6
AZ - Azerbaigian 4
BY - Bielorussia 4
GA - Gabon 4
GH - Ghana 4
HU - Ungheria 4
KG - Kirghizistan 4
KW - Kuwait 4
LU - Lussemburgo 4
MD - Moldavia 4
OM - Oman 4
RS - Serbia 4
UY - Uruguay 4
BH - Bahrain 3
NI - Nicaragua 3
QA - Qatar 3
SC - Seychelles 3
AM - Armenia 2
BZ - Belize 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
MK - Macedonia 2
MN - Mongolia 2
PA - Panama 2
Totale 32.677
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.847
Singapore 1.752
Hong Kong 1.534
Ashburn 1.222
Fairfield 858
Woodbridge 832
Chandler 728
Houston 688
Dublin 646
Frankfurt am Main 623
Wilmington 566
Milan 545
New York 415
Santa Clara 405
Jacksonville 385
Seattle 384
Dearborn 345
Ho Chi Minh City 317
Beijing 288
Dallas 283
Cambridge 280
Princeton 278
Hefei 251
Hanoi 233
Los Angeles 227
Jakarta 152
The Dalles 148
Nanjing 146
Altamura 128
Lawrence 124
São Paulo 115
Moscow 108
Vienna 106
Buffalo 104
Seoul 99
Council Bluffs 96
Shanghai 96
Chicago 91
Rome 90
Munich 89
Boardman 88
Helsinki 69
London 69
Guangzhou 67
San Diego 62
Lachine 60
Nuremberg 58
Toronto 52
Andover 51
Rio de Janeiro 50
Nanchang 47
Hangzhou 46
Shenyang 45
Dong Ket 43
Columbus 41
Tianjin 41
San Jose 40
Tokyo 40
Warsaw 40
Lappeenranta 39
Johannesburg 36
Haiphong 35
Ottawa 35
Fremont 34
Jinan 34
Poplar 34
Boston 33
Brooklyn 33
Brussels 33
Orem 33
Changsha 31
Da Nang 30
Zhengzhou 30
Jiaxing 29
Bologna 28
Denver 28
Hebei 28
Mexico City 28
Phoenix 28
Lissone 27
Paris 27
Atlanta 26
Brasília 26
Salt Lake City 26
Biên Hòa 25
Falls Church 25
Redmond 24
Stockholm 24
Verona 24
Montreal 23
Tampa 23
Chennai 22
Pune 22
Washington 22
Florence 21
Ningbo 21
Porto Alegre 20
San Francisco 20
Turin 20
Amsterdam 19
Totale 19.759
Salva come PNG Salva come JPEG
Nome #
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 519
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 437
Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women 424
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 400
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 397
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors 354
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review 352
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 336
Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis 325
Use of health care administrative databases to estimate the burden of breast cancer. 324
Use of health care administrative databases to estimate the burden of multiple sclerosis: a population-based study 318
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017 315
State of health and inequalities among Italian regions from 2000 to 2021: a systematic analysis based on the Global Burden of Disease Study 2021 312
Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 297
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 296
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 282
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 277
Health related quality of life in chronic liver diseases 276
Liver Transplantation in Alcohol-Associated Hepatitis. Benefits and Limitations of Psychosocial Selection and Support in Alcohol Relapse. The Experience of a Tertiary Center in Italy 268
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 264
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 263
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 261
Costs and effectiveness of influenza vaccination: A systematic review 259
Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017 256
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 255
The socioeconomic burden of patients affected by hemophilia with inhibitors 253
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 251
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 250
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 247
Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 246
The impact of liver disease on the health-related quality of life 244
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 243
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 243
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 242
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 242
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 242
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities 241
Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting 238
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors 236
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 235
Health Related Quality of Life in the Major Liver Conditions 235
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 234
Sustainability of the Italian National Health Service 231
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 227
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 227
Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 225
Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 224
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 217
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 217
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 216
Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: A systematic analysis for the Global Burden of Disease Study 2017 215
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 213
Models of The Impact of Major Liver Diseases on Eq-5d Visual Analogue Scale and Utility-Index: Convergences and Divergences 213
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 212
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 211
Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023 210
The Burden of Severe Hypoglicaemias and Diabetes Ketoacidosis: A Population-Based Study 208
Economic Burden of Urticaria Requiring Hospitalization: Analysis from an Administrative Database 208
Time-Trends in Air Pollution Impact on Health in Italy, 1990–2019: An Analysis From the Global Burden of Disease Study 2019 207
Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study) 207
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 207
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 206
Difference in health related quality of life of chronic liver diseases and general population 206
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 205
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 204
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study 204
Il burden delle polmoniti: analisi dai database amministrativi (DENALI) della regione Lombardia. 199
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 198
Economic Burden Of Stroke: Analysis From An Administrative Database 198
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 198
COVID-19 outbreak impact on anticoagulants utilization: an interrupted time-series analysis using healthcare administrative databases 196
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 194
Azithromycin use and outcomes in patients with COVID-19: an observational real-world study 193
Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products 193
2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation 192
Treatment patterns in essential tremor: Real-world evidence from a United Kingdom and France primary care database 191
Health related quality of life norm data of the general population in Italy: Results using the EQ-5D-3L and EQ-5D-5L instruments 190
Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era 190
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 190
Incidence of inhibitors to recombinant factor VIII products – A meta-analysis of 1,852 previously untreated patients 189
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 188
Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases 186
Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study 186
Utilization of disease modifying agents in multiple sclerosis: from an Italian administrative database. 184
Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions 184
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 183
Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis 180
Epidemiologic And Economic Burden Attributable To Atrial Fibrillation From Administrative Data 179
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 179
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 178
Preferenze della popolazione italiana per gli stati di salute dell'EQ-5D 177
Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view 177
Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: Results from Italy 175
Epidemiology and Direct Health Care Costs of Diabetic Retinopathy: Results From a Population-Based Study 175
Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases 175
Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data 174
Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database 172
Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1 172
Management of Chronic hepatitis C (CHC) Genotype 1 treatment-naive patients in an era of rising opportunities and costs - A cost-effectiveness analysis of treatment options 171
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 171
Totale 23.586
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.160
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.160
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.500 0 0 0 0 0 182 230 239 202 231 148 268
2021/20221.868 137 182 253 178 130 146 64 121 109 129 106 313
2022/20233.149 327 896 275 271 212 452 57 195 222 49 100 93
2023/20242.714 98 119 93 149 295 645 397 119 233 114 146 306
2024/20257.707 352 716 355 366 610 469 444 293 795 929 1.013 1.365
2025/20268.907 2.107 1.037 1.194 1.799 2.071 699 0 0 0 0 0 0
Totale 33.865